Profile: Cytomedix, Inc. develops biologically active regenerative therapies for wound care, angiogenesis, and inflammation. Our CT-112 is a drug candidate in early development which represents a therapeutic intervention that addresses inflammatory mediated disease. Our Autologel system utilizes a unique technology that enables rapid isolation and activation of platelet rich plasma from patients own blood. Our PRP system combines the patients' natural healing processes to provide growth factors, chemokines & cytokines known to promote angiogenesis and to regulate cell growth & formation of new tissue.